Zucara Therapeutics Inc.
October 18, 2023
Franciscan B
Metabolic Diseases
Zucara Therapeutics Inc. is developing ZT-01, a first-in-class therapeutic to prevent insulin-induced hypoglycemia (low blood sugar) in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin (SST), a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with Type 1 diabetes and insulin-dependent Type 2 diabetes (T1D). ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life.
Company Type
Privately Funded
Website
http://www.zucara.ca
CEO/Top Company Official
Michael Midmer
Lead Product in Development
ZT-01, is a SSTR2 receptor antagonist designed to normalize SST (somatostatin) signalling in the pancreas, which is dysregulated in diabetes and causes disruptive hypoglycemia (low blood sugar) events. Zucara is starting a Phase 2 study with ZT-01 in Q3, 2023.
Number Of Unlicensed Products
1
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)